Computer Aided Detection of Polyps in Colonoscopy

Sponsor
Iterative Scopes, Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT04754347
Collaborator
University of Minnesota (Other)
1,472
5
2
9.3
294.4
31.8

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the clinical benefit and safety of using a computer aided detection device, Skout, for real-time polyp detection in colonoscopy procedures with the indication of screening or surveillance. One of the reasons for the development of interval colorectal cancers is polyps missed during colonoscopy. Our hypothesis is that with the aid of Skout, the adenomas detected per colonoscopy will increase, and it is plausible to believe that this increase in detection could reduce the incidence of interval cancers.

Condition or Disease Intervention/Treatment Phase
  • Device: Computer Aided Detection device
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1472 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Screening
Official Title:
Randomized, Controlled Trial of a Computer Aided Detection Device in Standard Colonoscopy
Actual Study Start Date :
Jan 22, 2021
Actual Primary Completion Date :
Oct 31, 2021
Actual Study Completion Date :
Oct 31, 2021

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Routine Colonoscopy

Experimental: Experimental

Routine Colonoscopy with the use of Skout

Device: Computer Aided Detection device
The Computer Aided Detection device, Skout, is designed to help endoscopists detect potential colorectal polyps during colonoscopies. The system performs automated real-time analysis on endoscopic video data to identify potential polyps and produces an informational visual aid around the appropriate sections of the video frames on a display monitor.

Outcome Measures

Primary Outcome Measures

  1. Adenomas per colonoscopy [At the end of the procedure, 1 day]

    The total number of adenomas detected divided by the total number of colonoscopies.

  2. Positive predictive value [At the end of the procedure, 1 day]

    The total number of adenomas and serrated lesions detected divided by the total number of extractions.

Secondary Outcome Measures

  1. Adenoma detection rate [At the end of the procedure, 1 day]

    The percentage of participants aged ≥50 years undergoing first-time screening colonoscopy who have one or more conventional adenomas detected.

  2. Sessile serrated lesions detected [At the end of the procedure, 1 day]

    The total number of polyps with histology or serrated adenoma, traditional serrated adenoma or serrated lesion with cytological dysplasia, excluding hyperplastic polyps.

  3. Colorectal cancer surveillance interval [At the end of the procedure, 1 day]

    The mean recommended timeframe for follow up colonoscopy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

Participants will be eligible for this study if they are:
  • Undergoing colonoscopy with screening, surveillance, or diagnostic indications.

  • Undergoing a procedure by a participating endoscopist.

  • Have given informed consent.

Exclusion Criteria

Participants will not be eligible for this study if they:
  • Have a history of inflammatory bowel disease.

  • Have a history of familial adenomatous polyposis.

  • Are under the age of 40.

  • Have had a colonoscopy within the previous three (3) years.

  • Undergoing diagnostic colonoscopy with high-risk indications including iron deficiency anemia, abnormal CT imaging, unexplained weight loss, Lynch Syndrome, blood in stool or FIT positive test.

  • Entered with poor bowel preparation (inadequate for procedure as assessed by the Investigator).

  • Use anti-platelet agents or anticoagulants that preclude the removal of polyps during the procedure.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114
2 Boston Medical Center Boston Massachusetts United States 02118
3 Mount Auburn Hospital Cambridge Massachusetts United States 02138
4 MNGI Digestive Health Plymouth Minnesota United States 55446
5 Concord Endoscopy Center Concord New Hampshire United States 03301

Sponsors and Collaborators

  • Iterative Scopes, Inc
  • University of Minnesota

Investigators

  • Principal Investigator: Aasma Shaukat, MD, MPH, University of Minnesota

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Iterative Scopes, Inc
ClinicalTrials.gov Identifier:
NCT04754347
Other Study ID Numbers:
  • Pro00047634
First Posted:
Feb 15, 2021
Last Update Posted:
Dec 1, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Iterative Scopes, Inc
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 1, 2021